Recently, Anhui ANKE Bio Engineering (Group) Co., Ltd (hereinafter referred to as "ANKE Bio", stock code: 300009) signed a license agreement with Shanghai Shijian Biotechnology Co. ("ANKE Bio"). According to the license agreement, ANKE Bio has formally obtained the license of EZWi-Fit®, the ADC technology platform of SHIJIAN BIOLOGY, to develop ADC products. During the license period, ANKE Bio will be responsible for the preclinical research, clinical development and commercial production and sales of the developed products in Greater China, and will pay equity payments (including down payment and milestone payments) and a sales commission as a percentage of net sales to SHIJIAN BIO. Shijian Bio acquires an overseas interest in the ADC product.

Shijian Bio is a clinical-stage ADC new drug discovery and development company with an ADC clinical pipeline and comprehensive new drug discovery and development capabilities, and has established a new-generation ADC technology platform, EZWi-Fit®, with its own intellectual property rights.

This collaboration is an important milestone for ANKE Bio and Shijian Bio to deepen their cooperation.

Dr. Zhou Qing, Founder and CEO of Shijian Bio, said: ANKE Bio, one of the first GEM-listed companies, is one of the leading companies in the biopharmaceutical industry with comprehensive development in all aspects of product development, production and sales. We are very pleased to see the application of the EZWi-Fit® platform technology to the ADC new drug discovery program, allowing the platform technology to expand to more targets and clinical indications, benefiting more patients. Shijian Bio would like to thank ANKE Bio for their high recognition of the EZWi-Fit® technology platform and their trust in Shijian. Shijian will fully provide technical support for a win-win cooperation and looks forward to the early entry of the project into clinical trials for the benefit of patients.

Dr. Li-Hua Song, Chairman of ANKE Bio, said: "We are very pleased to enter into this collaboration with SHIJIAN. We are very pleased to enter into this cooperation with Shijian Bio. Shijian Bio focuses on the early development of ADC drugs, while ANKE Bio has accumulated rich experience in the clinical advancement, industrialization and commercialization of biologics for many years. We hope that through this cooperation, both parties will complement each other's strengths and continue to cooperate in a comprehensive and in-depth manner to achieve mutual benefits and win-win results, as well as to further consolidate and strengthen the advantages of both parties in their respective fields.

https://mp.weixin.qq.com/s?__biz=MzI1MTIzNDY0Nw==&mid=2247498878&idx=1&sn=009884e1afc66f17e2ae673b8c1c5b44&chksm=e9f4ac46de83255028558111156be60d06133c16dbbc7f3b68dc66ccbbbff05e6072cb579543&mpshare=1&scene=1&srcid=0418dEBGIVdnannizsI60Wsu&sharer_shareinfo=79d1f2d471221f4bb970a65f2f5936a6&sharer_shareinfo_first=79d1f2d471221f4bb970a65f2f5936a6#rd